 therapy for the treatment of Gaucher disease. Using a similar test model as designed for chaperone therapy in Fabry disease, candidate active-site-directed molecules are under investigation. All surviving patients with Gaucher disease have residual glucocerebrosidase activity and appear to be excellent candidates for molecular chaperone
therapy for the treatment of Gaucher disease. Using a similar test exemplar as design for chaperone therapy in Fabry disease, candidate active - site - target molecules are under investigation. All outlive affected role with Gaucher disease have residual glucocerebrosidase action and appear to be excellent candidates for molecular chaperon
 thfrapy for the treatment uf Gaucher disecwe. Usiig a sijilar tert model as designed for cha'erobe thtgapy in Fabry disease, candidatv active-sute-dmrected molecules are under inbcstigctmon. All survivikg patients with Gaucher girecse have residual glucocerebrosidase activiyy and appear to be txcqllehn gandidates for molecular chaperohe
therapy for the treatment of Gaucher disease. similar model as for chaperone therapy molecules under investigation. All patients with Gaucher have residual glucocerebrosidase activity and appear be excellent candidates for molecular chaperone
 therapy for the treatment of GAucher diseAse. UsIng A siMiLar tEst mOdel as designed FOr chAperone therapy in Fabry dIseasE, cANdidATe ActivE-site-diREcTED moLeCuLes ArE UnDer inVesTigatioN. All survivIng PaTients with GaUChEr disease hAve Residual glucOceRebrosIdAse ACtiviTy aNd appEar to bE ExcellEnt candidAtES for moLEcular cHAPeRone
 therapy for the treatment  of Gauche r dis eas e.Us inga si milar test mod e l as  designed for chaperon e the ra p y in Fa bry d isease, ca n d ida te  a cti ve - si te-di rec ted mol ecules are  un de r investigat i on . All surv ivi ng patientswit h Gauc he r d i sease  ha ve re sidual glucoc erebrosid as e  activ i ty anda p pe ar t o be excellent ca n di d ates for molec ular c ha p er o n e
 therapy_for the_treatment of Gaucher disease._Using a_similar_test model_as_designed for chaperone_therapy in Fabry_disease, candidate active-site-directed molecules_are under investigation._All_surviving patients with Gaucher disease have residual glucocerebrosidase activity and appear to be excellent_candidates_for molecular_chaperone